Company Performance Metrics
CytoHub is revolutionizing cardiac regenerative medicine with hypo-immune iPSC-derived cardiomyocytes that enable superior engraftment, immune evasion, and physiological function. Our AI-powered human mini-heart platform is transforming drug discovery, disease modeling, and heart muscle regeneration—paving the way for breakthrough therapies in
cardiovascular care. Our innovation's core is to scale high-throughput drug screening and cell therapy manufacturing, advancing BioEngineAI— our proprietary AI/ML-powered automation system integrating robotics. Combined with our proprietary iPSC differentiation method, we produce cardiomyocyte assembloids with unmatched physiological maturity—unlocking a $1.6T+ market opportunity to treat myocardial infarction and restore heart function.
